Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to -$56.9 million.

  • 4D Molecular Therapeutics' Net Income towards Common Stockholders fell 29.73% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.2 million, marking a year-over-year decrease of 45.79%. This contributed to the annual value of -$160.9 million for FY2024, which is 59.53% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$56.9 million for Q3 2025, which was down 4.06% from -$54.7 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$7.6 million during Q2 2021, with a 5-year trough of -$56.9 million in Q3 2025.
  • Over the past 3 years, 4D Molecular Therapeutics' median Net Income towards Common Stockholders value was -$35.0 million (recorded in 2024), while the average stood at -$38.3 million.
  • In the last 5 years, 4D Molecular Therapeutics' Net Income towards Common Stockholders spiked by 60.08% in 2023 and then tumbled by 327.49% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$25.1 million in 2021, then fell by 9.15% to -$27.4 million in 2022, then declined by 17.91% to -$32.3 million in 2023, then crashed by 53.86% to -$49.7 million in 2024, then declined by 29.73% to -$56.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$56.9 million for Q3 2025, versus -$54.7 million for Q2 2025 and -$48.0 million for Q1 2025.